. . . . . . . . . . "a(CHEBI:erlotinib) -| path(SDIS:\"tumor growth\")" . "Approximately 61,000 statements." . "Copyright (c) 2011-2012, Selventa. All rights reserved." . "BEL Framework Large Corpus Document" . . "1.4" . "Epidermal growth factor receptor (EGFR)–specific tyrosine kinase inhibitors (TKI) gefitinib and erlotinib have been developed as therapeutic agents for non–small cell lung cancer (NSCLC) treatment (1, 2, 3)." . . "Selventa" . . . . "2014-07-03T14:30:53.189+02:00"^^ . . .